Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib in moderate to severe atopic dermatitis
NCT03435081Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2018
- Primary completion
- Dec 2019
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of baricitinib in atopic dermatitis (AD) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Percentage of Participants Achieving Eczema Area and Severity Index 75 at 16 weeks. Started Feb 2018; status: completed.
02
Drugs
baricitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03435081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03435081.